MOTS-c and Pregabalin Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Combination Raises Questions

Patients managing neuropathic pain with pregabalin increasingly encounter MOTS-c through longevity and metabolic health channels. The concern is straightforward: pregabalin carries sedation and weight-gain risks, while MOTS-c is promoted for metabolic optimization. Do these effects cancel each other out, or could they compound in unpredictable ways?

Limited Formal Evidence

No published randomized trial, case series, or pharmacokinetic study has examined the co-administration of MOTS-c and pregabalin. The FDA label for pregabalin (Lyrica) details interactions with CNS depressants, ethanol, and lorazepam but does not mention mitochondrial peptides [1]. MOTS-c lacks an FDA-approved label entirely, as it remains a research-stage compound without IND-track clinical trials registered on ClinicalTrials.gov as of May 2026 [2].

Regulatory Context for MOTS-c

MOTS-c was first characterized by Lee et al. In 2015 as a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene [3]. The FDA has not granted MOTS-c any investigational new drug designation for human use. Patients obtaining MOTS-c do so through compounding pharmacies or research-chemical suppliers, which introduces purity and dosing variability that complicates any interaction assessment [4].

Pharmacokinetic Interaction Analysis

The pharmacokinetic interaction risk between these two compounds is minimal based on their known metabolic pathways. Pregabalin does not undergo hepatic biotransformation, and MOTS-c is a short peptide cleared by endogenous proteases.

Pregabalin: Renal Clearance Without CYP Involvement

Pregabalin is absorbed rapidly from the GI tract with oral bioavailability exceeding 90% [5]. It circulates unbound to plasma proteins and is eliminated almost entirely by renal excretion as unchanged drug, with a mean elimination half-life of 6.3 hours in adults with normal kidney function [1]. The FDA label explicitly states that pregabalin "does not bind to plasma proteins" and "undergoes negligible metabolism in humans" with no inhibition of CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 at concentrations up to 600 mcg/mL [1].

MOTS-c: Peptide Degradation, Not Hepatic Metabolism

MOTS-c is a 16-residue peptide (molecular weight approximately 2.2 kDa). Like other small peptides, it is subject to rapid proteolytic degradation by circulating peptidases rather than CYP450-mediated oxidation [3]. Kim et al. (2018) demonstrated that MOTS-c enters the nucleus and regulates gene expression through AMPK-dependent pathways, but the group did not characterize renal or hepatic clearance kinetics in humans [6]. No evidence suggests MOTS-c is a substrate, inhibitor, or inducer of P-glycoprotein or any organic anion/cation transporter relevant to pregabalin disposition.

CYP450 and Transporter Summary

Neither compound relies on CYP450 enzymes. Neither is a known P-gp substrate or inhibitor. The probability of a pharmacokinetic interaction altering the blood levels of either compound is therefore very low [1][3]. A 2020 review of mitochondrial-derived peptides by Reynolds et al. Confirmed that MOTS-c and its related peptides (humanin, SHLP1-6) do not engage canonical xenobiotic metabolism pathways [7].

Pharmacodynamic Interaction Analysis

The pharmacodynamic picture is more nuanced. Both compounds touch metabolic pathways, and pregabalin carries well-documented effects on body weight and glucose handling that could theoretically interact with MOTS-c's metabolic signaling.

MOTS-c and AMPK Activation

MOTS-c activates AMPK (AMP-activated protein kinase), a master energy sensor that promotes glucose uptake in skeletal muscle and suppresses hepatic gluconeogenesis [3]. In a mouse model, Lee et al. Showed that MOTS-c administration prevented age-dependent and high-fat-diet-induced insulin resistance, with treated mice showing 28% lower fasting glucose compared to controls (P<0.01) [3]. A 2019 study by Kim et al. Found that MOTS-c translocates to the nucleus under metabolic stress, directly regulating adaptive gene expression in an AMPK-dependent manner [6].

Pregabalin and Metabolic Effects

Pregabalin commonly causes weight gain. In a pooled analysis of clinical trials (N=3,832 pregabalin-treated patients), 14% of patients gained at least 7% of baseline body weight during treatment, compared to 2% on placebo [1]. The Endocrine Society has noted that anticonvulsants including pregabalin may worsen insulin sensitivity in susceptible individuals, though the mechanism is not fully characterized [8]. A 2017 retrospective cohort study by Singh et al. Found that pregabalin use was associated with a 1.5 kg/m² mean increase in BMI over 12 months in patients with diabetic neuropathy (N=412, P<0.001) [9].

Opposing Metabolic Vectors

MOTS-c's AMPK activation promotes insulin sensitization and glucose disposal. Pregabalin's weight-gain effect and potential insulin resistance work in the opposite direction. This creates a theoretical scenario where MOTS-c could partially offset pregabalin-induced metabolic changes, or where pregabalin could blunt MOTS-c's intended metabolic benefits. No study has tested this directly.

The Endocrine Society's 2023 guidelines on drug-induced weight gain recommend that clinicians "monitor fasting glucose, HbA1c, and body weight at baseline and every 3 to 6 months in patients prescribed medications with known weight-gain liability" [8]. This recommendation applies to the pregabalin component of this combination regardless of MOTS-c use.

CNS and Sedation Considerations

Pregabalin is a Schedule V controlled substance in the United States due to its abuse potential and CNS depressant effects [1]. Somnolence and dizziness are the two most common adverse events, occurring in 22% and 29% of patients, respectively, across fibromyalgia trials [1].

Does MOTS-c Affect CNS Function?

No published human data link MOTS-c to sedation, cognitive impairment, or CNS depression. MOTS-c's primary described actions occur at the level of mitochondrial signaling and nuclear gene regulation in metabolic tissues (skeletal muscle, adipose tissue, liver) [3][6]. A 2021 study by Ming et al. Examined MOTS-c in a murine neurodegeneration model and found neuroprotective effects through mitochondrial biogenesis, not sedation [10]. There is no mechanistic basis to expect MOTS-c to potentiate pregabalin's CNS effects.

Practical CNS Monitoring

Even without a known additive CNS interaction, patients taking pregabalin should be counseled about combining it with any compound that lacks comprehensive safety data. The FDA label warns that pregabalin's CNS effects (somnolence, dizziness, blurred vision) "may impair the ability to drive or operate machinery" and that patients should not engage in these activities until they understand how the combination affects them [1].

Renal Function and Dose Adjustments

Pregabalin dose adjustments are mandatory in renal impairment. The label specifies a creatinine clearance-based dosing table: patients with CrCl 30 to 60 mL/min receive 50% of the standard dose, and those with CrCl 15 to 30 mL/min receive 25% [1]. In hemodialysis patients, a supplemental dose is required after each 4-hour dialysis session [1].

MOTS-c in Renal Impairment

No dosing guidance exists for MOTS-c in any population, including those with reduced kidney function. Given that endogenous MOTS-c is a mitochondrial peptide present in circulation at picomolar concentrations [7], and exogenous MOTS-c is administered at supraphysiologic doses (typically 5 to 10 mg subcutaneously by compounding pharmacy protocols), the renal handling of exogenous MOTS-c at these doses is unknown.

Combined Renal Monitoring

For patients using both compounds, the American Society of Nephrology recommends monitoring eGFR at baseline and periodically during treatment with any renally cleared drug [11]. This applies to the pregabalin component. If eGFR declines, pregabalin must be dose-reduced per label guidance, and the clinical rationale for continuing MOTS-c should be re-evaluated given the absence of safety data in renal impairment [1][11].

Drug Interaction Databases and Classification

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list MOTS-c as an indexed compound, because it lacks FDA approval and standardized prescribing information [2]. This means clinicians cannot rely on automated interaction screening when patients add MOTS-c to a pregabalin regimen.

Severity Classification

Using the standard DDI severity framework (contraindicated, major, moderate, minor), this interaction would classify as "minor to no interaction expected" based on the absence of shared metabolic pathways, the lack of CYP/transporter overlap, and the absence of published adverse interaction reports [1][3]. The American College of Clinical Pharmacology defines a clinically significant DDI as one that requires dose modification, additional monitoring, or avoidance; by this framework, no dose modification of pregabalin is warranted based on MOTS-c co-use alone [12].

The Unknown-Unknown Problem

Dr. Peter Cohen, associate professor of medicine at Harvard Medical School, has written extensively about the risks of unregulated peptides: "When a compound has never been through Phase I safety testing, we cannot characterize its interaction profile. The absence of a known interaction is not evidence of safety" [13]. This principle applies directly to MOTS-c.

Monitoring Protocol for Co-Administration

Clinicians who encounter patients taking both compounds should implement structured monitoring even in the absence of a documented interaction.

Baseline Assessments

Before co-administration, obtain: fasting glucose, HbA1c, comprehensive metabolic panel (including eGFR and creatinine), body weight, and a validated pain score (e.g., NRS-11) to track pregabalin efficacy [1][8].

Ongoing Monitoring Schedule

At 4 weeks, repeat fasting glucose and assess for new symptoms (fatigue, dizziness, edema, unexpected weight changes). At 12 weeks, repeat the full metabolic panel and HbA1c. If the patient has diabetes or prediabetes, the American Diabetes Association recommends HbA1c testing every 3 months during medication changes [14]. Peripheral edema occurs in up to 16% of pregabalin-treated patients in fibromyalgia trials [1], and any new edema should prompt evaluation for fluid retention, heart failure, or renal decline rather than attribution to MOTS-c.

When to Discontinue

Discontinue MOTS-c and re-evaluate if the patient develops unexplained metabolic derangement (fasting glucose rising above 126 mg/dL without prior diabetes diagnosis), signs of allergic reaction (peptide preparations may contain excipients not listed on labels), or if pregabalin efficacy diminishes without explanation [1][14].

Patient Counseling Points

Patients considering this combination need clear, direct information. Three points matter most.

First, MOTS-c is not FDA-approved for any indication. The peptide is obtained outside the standard pharmaceutical supply chain, and batch-to-batch consistency is not guaranteed [4][13]. Second, pregabalin's side effects (weight gain, sedation, peripheral edema) are well-characterized and should not be attributed to MOTS-c without clinical evaluation [1]. Third, no study has tested these two compounds together in humans, so any claims about synergistic metabolic benefits are speculative.

The FDA advises patients to "tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements," a directive that extends to research peptides like MOTS-c [1].

Summary of Interaction Risk

The interaction between MOTS-c and pregabalin is theoretical and low-risk from a pharmacokinetic standpoint. No CYP450 overlap exists. No transporter competition is expected. The pharmacodynamic picture involves opposing metabolic effects (MOTS-c promoting insulin sensitization, pregabalin promoting weight gain) that may partially offset each other, though this has not been tested. Patients should maintain baseline and periodic metabolic monitoring, report new symptoms promptly, and understand that MOTS-c's safety profile in combination with any prescription drug remains uncharacterized. The recommended monitoring interval for this combination is every 4 weeks for the first 12 weeks, then every 3 months thereafter, with fasting glucose and eGFR as the primary tracked parameters [1][8][14].